Serena S Spudich1. 1. Department of Neurology, Yale University, New Haven, Connecticut, USA.
Abstract
PURPOSE OF REVIEW: Robust and dynamic innate and adaptive responses characterize the acute central nervous system (CNS) response to HIV and other viral infections. In a state of chronic infection or viral latency, persistent immune activation associates with abnormality in the CNS. Understanding this process is critical, as immune-mediated abnormality in nonrenewable CNS cells may result in long-term neurologic sequelae for HIV-infected individuals. RECENT FINDINGS: In humans, immune activation is reduced by suppressive combination antiretroviral therapy, but persists at abnormally elevated levels on treatment. CNS immune activation is initiated in acute infection and progressively increases until combination antiretroviral therapy is started. Newly identified characteristics of the CNS immune surveillance network include features of homeostasis and function of brain microglial cells, lymphatic drainage from CNS to cervical lymph nodes, and cells in cerebrospinal fluid associated with neurocognitive impairment. SUMMARY: More research is required to determine whether early intervention to reduce infection limits the immunopathology established by sustained immune responses that ultimately fail to resolve infection, and to unravel mechanisms of persistent immune activation during treated HIV so that strategies can be developed to therapeutically protect the brain.
PURPOSE OF REVIEW: Robust and dynamic innate and adaptive responses characterize the acute central nervous system (CNS) response to HIV and other viral infections. In a state of chronic infection or viral latency, persistent immune activation associates with abnormality in the CNS. Understanding this process is critical, as immune-mediated abnormality in nonrenewable CNS cells may result in long-term neurologic sequelae for HIV-infected individuals. RECENT FINDINGS: In humans, immune activation is reduced by suppressive combination antiretroviral therapy, but persists at abnormally elevated levels on treatment. CNS immune activation is initiated in acute infection and progressively increases until combination antiretroviral therapy is started. Newly identified characteristics of the CNS immune surveillance network include features of homeostasis and function of brain microglial cells, lymphatic drainage from CNS to cervical lymph nodes, and cells in cerebrospinal fluid associated with neurocognitive impairment. SUMMARY: More research is required to determine whether early intervention to reduce infection limits the immunopathology established by sustained immune responses that ultimately fail to resolve infection, and to unravel mechanisms of persistent immune activation during treated HIV so that strategies can be developed to therapeutically protect the brain.
Authors: Aylin Yilmaz; Chris Verhofstede; Antonio D'Avolio; Victoria Watson; Lars Hagberg; Dietmar Fuchs; Bo Svennerholm; Magnus Gisslén Journal: J Acquir Immune Defic Syndr Date: 2010-12-15 Impact factor: 3.731
Authors: James T Becker; Joanne Sanders; Sarah K Madsen; Ann Ragin; Lawrence Kingsley; Victoria Maruca; Bruce Cohen; Karl Goodkin; Eileen Martin; Eric N Miller; Ned Sacktor; Jeffery R Alger; Peter B Barker; Priyanka Saharan; Owen T Carmichael; Paul M Thompson Journal: Brain Imaging Behav Date: 2011-06 Impact factor: 3.978
Authors: John G Walsh; Stacey N Reinke; Manmeet K Mamik; Brienne A McKenzie; Ferdinand Maingat; William G Branton; David I Broadhurst; Christopher Power Journal: Retrovirology Date: 2014-05-13 Impact factor: 4.602
Authors: Jennifer H Campbell; Tricia H Burdo; Patrick Autissier; Jeffrey P Bombardier; Susan V Westmoreland; Caroline Soulas; R Gilberto González; Eva-Maria Ratai; Kenneth C Williams Journal: PLoS One Date: 2011-04-06 Impact factor: 3.240
Authors: Oliver M Grauer; Doris Reichelt; Ute Grüneberg; Hubertus Lohmann; Tilman Schneider-Hohendorf; Andreas Schulte-Mecklenbeck; Catharina C Gross; Sven G Meuth; Heinz Wiendl; Ingo W Husstedt Journal: Ann Clin Transl Neurol Date: 2015-08-18 Impact factor: 4.511
Authors: Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Kathleen M Malee; Miriam C Chernoff; Patricia A Sirois; Paige L Williams; Patricia A Garvie; Betsy L Kammerer; Lynnette L Harris; Molly L Nozyce; Cenk Yildirim; Sharon L Nichols Journal: J Acquir Immune Defic Syndr Date: 2017-08-01 Impact factor: 3.731
Authors: E Merlini; F Iannuzzi; A Calcagno; F Bai; M Trunfio; A d'Arminio Monforte; S Bonora; Giulia Marchetti Journal: J Neurovirol Date: 2018-07-09 Impact factor: 2.643
Authors: Leah H Rubin; Scott A Langenecker; K Luan Phan; Sheila M Keating; Gretchen N Neigh; Kathleen M Weber; Pauline M Maki Journal: Psychoneuroendocrinology Date: 2020-02-07 Impact factor: 4.905